🟢 Tvardi Therapeutics is trading 8.9% up in pre-market

Tvardi Therapeutics is trading at $1.10, up 8.91% in pre-market on October 19, 2026; the reason for the move is unclear.

• The company’s investor-relations page lists its latest release as September 24, about preclinical data; that earlier update does not establish the reason for this move.
• The supplied sector context is negative and major-index context is positive, so neither clearly explains the gain.